Efficient and Accurate Modeling of Conformational Transitions in Proteins: The Case of c-Src Kinase.
暂无分享,去创建一个
Domenico Raimondo | Marco D'Abramo | Edoardo Milanetti | Josephine Alba | D. Raimondo | M. D’Abramo | E. Milanetti | Alexandra G Trandafir | Josephine Alba | Alexandra G. Trandafir
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] G. Martin,et al. The road to Src , 2004, Oncogene.
[3] Sevgi Irtegun,et al. Deregulation of c‐Src tyrosine kinase and its downstream targets in pre‐eclamptic placenta , 2017, The journal of obstetrics and gynaecology research.
[4] R. Roskoski,et al. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. , 2015, Pharmacological research.
[5] Andrew E. Torda,et al. Local elevation: A method for improving the searching properties of molecular dynamics simulation , 1994, J. Comput. Aided Mol. Des..
[6] Z. Zhao,et al. A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] Michael J. Eck,et al. Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.
[8] Elif Ozkirimli,et al. Src kinase activation: A switched electrostatic network , 2006, Protein science : a publication of the Protein Society.
[9] E. Altmann,et al. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. , 2002, Mini reviews in medicinal chemistry.
[10] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[11] Valentina Tozzini,et al. Coarse-grained models for proteins. , 2005, Current opinion in structural biology.
[12] Diwakar Shukla,et al. Transition path theory analysis of c-Src kinase activation , 2016, Proceedings of the National Academy of Sciences.
[13] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[14] D. Wheeler,et al. The role of Src in solid tumors. , 2009, The oncologist.
[15] S. Dehm,et al. SRC gene expression in human cancer: the role of transcriptional activation. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[16] R. Roskoski,et al. Src protein-tyrosine kinase structure and regulation. , 2004, Biochemical and biophysical research communications.
[17] T. Mulhern,et al. Tyrosine 416 Is Phosphorylated in the Closed, Repressed Conformation of c-Src , 2013, PloS one.
[18] M. Guarino. Src signaling in cancer invasion , 2010, Journal of cellular physiology.
[19] Grubmüller,et al. Predicting slow structural transitions in macromolecular systems: Conformational flooding. , 1995, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.
[20] Dihua Yu,et al. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. , 2012, Trends in pharmacological sciences.
[21] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[22] Benoît Roux,et al. Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..
[23] D. van der Spoel,et al. GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .
[24] H. Varmus,et al. Association of the amino‐terminal half of c‐Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. , 1994, The EMBO journal.
[25] D. Fabbro,et al. SRC family kinases: potential targets for the treatment of human cancer and leukemia. , 2003, Current pharmaceutical design.
[26] V. Pande,et al. Activation pathway of Src kinase reveals intermediate states as novel targets for drug design , 2014, Nature Communications.
[27] Benoît Roux,et al. Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. , 2014, Journal of molecular biology.
[28] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[29] C. Baldari,et al. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. , 2008, Current medicinal chemistry.
[30] Giovanni Chillemi,et al. Modeling conformational transitions in kinases by molecular dynamics simulations: achievements, difficulties, and open challenges , 2014, Front. Genet..
[31] H J Berendsen,et al. An efficient method for sampling the essential subspace of proteins. , 1996, Journal of biomolecular structure & dynamics.
[32] M. Parrinello,et al. Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.
[33] Andrea Amadei,et al. Molecular mechanisms of activation in CDK2 , 2014, Journal of biomolecular structure & dynamics.
[34] R. Dror,et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.
[35] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[36] K. Gibson,et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.
[37] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[38] W. Miller,et al. Processive phosphorylation: mechanism and biological importance. , 2007, Cellular signalling.